This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Momenta Pharmaceuticals CEO Hosts Investor Conference Call To Discuss Follow-On Biologics Collaboration With Baxter (Transcript)

Momenta Pharmaceuticals, Inc. (MNTA)

Baxter International Inc. Collaboration Conference Call

December 23, 2011 10:00 am ET


Beverly Holley – Director, Investor Relations

Craig A. Wheeler – President and Chief Executive Officer

Richard P. Shea – Chief Financial Officer

Ganesh Venkataraman Ph.D. – Senior Vice President, Chief Scientific Officer


Ritu Baral – Canaccord Genuity

Sapna Srivastava – Goldman Sachs

Ami Fadia – UBS

Eric Schmidt – Cowen & Company

Bret Holley – Oppenheimer & Co.

Sumant Kulkarni – Bank of America/Merrill Lynch

Joseph P. Schwartz – Leerink Swann & Company

Duane Nash – Wedbush Securities

Alan Sonnenfeld – Bernstein

Avik Roy – Monness, Crespi, Hardt

Rajeev Jashnani – UBS Investment Bank

Frank Rango – Purchase Capital Management



Good day, ladies and gentlemen, and welcome to the Momenta Biosimilars Update. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to introduce your host for today's conference, Beverly Holley, Director of Investor Relations.

Beverly Holley

Thank you, and good morning. I want to welcome all of you to Momenta's conference call to discuss our recently-announced follow-on biologics collaboration with Baxter. With me on the call today with prepared remarks is Craig Wheeler, our President and Chief Executive Officer. Also present are Rick Shea, our CFO, and Ganesh Venkataraman, our Chief Scientific Officer. Following our remarks, we will open the call to questions.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs